US Pharma Services Market Sizing and 2025 Update
Directional U.S. pharma services market sizing across specialty pharmacy, prior authorization and reimbursement support, copay programs, market access consulting, data/RWE, and commercial technology, with the 2025 banking-report update folded into one public market map.
Curated by Rx Almanac using company materials, public reporting, and editorial synthesis.
On this page
Save this comparison — email yourself the full breakdown.
Join 200+ biotech launch teams on the weekly digest.
Thesis
The combined 2024 services revenue pool is directionally a mid-$40B market growing toward the mid-to-high $60B range by 2028. For buyers, that growth does not mean every vendor category deserves equal procurement attention. The most defensible spend is where specialty-drug complexity, regulatory deadlines, payer friction, or proprietary data create durable operating need rather than one-time consulting demand.
Implications
For manufacturer planning: Budget decisions should follow launch friction, not vendor taxonomy. A specialty product with heavy PA, accumulator exposure, and limited distribution needs coordinated spend across hub, reimbursement, affordability, SP network design, and data visibility.
For vendor diligence: Market size alone is a weak selection signal. Buyers should test whether a vendor owns a scarce workflow position: payer or EHR connectivity, specialty pharmacy network control, adjudication infrastructure, proprietary RWE assets, CRM migration expertise, or therapeutic-area operating depth.
For portfolio strategy: IRA, CMS-0057-F, PBM reform, and RWE adoption are cross-category catalysts. Vendors that can translate those catalysts into measurable access speed, adherence, gross-to-net control, or evidence generation should be favored over broad platforms that only aggregate services.
For competitive mapping: Expect continued consolidation across the six categories, but do not assume platform breadth equals buyer fit. PE-backed and distributor-backed platforms can offer scale, while focused specialists may remain the better choice for rare disease, oncology, cell/gene therapy, or data-intensive evidence use cases.
Overview
This consolidated market map sizes six U.S. pharma services revenue pools that matter to manufacturer launch, access, evidence, and commercialization teams. The directional model points to approximately $45—47 billion in 2024 U.S. services revenue, growing toward $64—68 billion by 2028 if specialty-drug complexity, reimbursement automation, data/RWE adoption, and commercial-technology modernization continue on current trajectories.
The page now absorbs the prior 2025 market-update article. That update was useful as banking-sector context, but it was not a separate market-sizing surface: Houlihan Lokey and Bourne Partners describe a rebound in pharma services M&A appetite and outsourcing demand, while the category-by-category buyer map below remains the stronger public asset.
Summary Table
| # | Category | 2024 US Market Size | 2028E US Market Size | CAGR (2024—2028) | Key Driver |
|---|---|---|---|---|---|
| 1 | Specialty Pharmacy | ~$25B | ~$32—36B | ~7—9% | Pipeline growth; gene/cell therapy; rare disease |
| 2 | Prior Auth, Reimbursement & Hub Support | ~$5B | ~$8.5B | ~14% | CMS-0057 FHIR mandate; AI automation; specialty PA volume |
| 3 | Copay & Financial Assistance | ~$1.0B | ~$1.4B | ~8—10% | Specialty launch volumes; accumulator mitigation; IRA Part D |
| 4 | Market Access Consulting | ~$3.4B | ~$5.0B | ~10% | IRA Medicare negotiation; biosimilar competition; PBM reform |
| 5 | Data Analytics & RWE | ~$8.5B | ~$13.8B | ~13% | FDA RWE framework; value-based contracts; AI/ML integration |
| 6 | Commercial Technology | ~$2.4B | ~$3.4B | ~9—11% | Vault CRM migration; AI/NBA; HCP digital shift |
| Combined | ~$45—47B | ~$64—68B | ~10—12% |
Boundary note: Cat. 2 includes hub and patient-access work only where the purchased job is benefits verification, PA, reimbursement support, or therapy-initiation workflow. Standalone hub-platform selection belongs in the hub services category. Cat. 5 and Cat. 6 both map to the public data / technology category, but they are separate revenue pools: data/RWE assets versus commercial workflow software.
Methodology note: These are directional editorial estimates, not audited market-research figures. The model triangulates public specialty dispensing data, PA transaction benchmarks, company financial disclosures, and sector banking reports, including Drug Channels specialty-pharmacy data, CAQH administrative-cost benchmarks, IQVIA and Veeva public financials, Houlihan Lokey’s 2025 pharma services update, and Bourne Partners’ commercialization / market-access report.
2025 Market Update Signals
- Outsourcing demand shifted upstream. Bourne Partners frames market access, HEOR/RWE, medical affairs, patient support, and hub services as earlier lifecycle decisions because payer evidence and launch economics now need to be designed before approval.
- New-launch economics remain the demand base. Bourne estimates $125 billion of expected annual net sales from new drug brand launches over the next five years, up from roughly $95 billion over the prior five years excluding COVID-19 products.
- Tech-enabled services carry valuation premium. Houlihan Lokey’s 2025 public-comps snapshot shows tech-enabled pharma services at 19.2x EV/NTM EBITDA, above total pharma services at 16.7x and distributors at 14.7x.
- Regulatory and pipeline signals still support specialized services. FDA recorded 50 novel drug approvals in 2024, and the 2025 banking reports emphasize orphan/rare disease, biologics, RWE, AI-enabled workflow, and patient-support complexity as the service categories with the strongest strategic pull.
1. Specialty Pharmacy Services
Market Definition
Revenue retained by pharmacies from dispensing specialty drugs: dispensing fees and spread revenue, manufacturer hub/service fees ($50—300/patient/month), 340B program margins at health-system pharmacies, specialty generic markups, and clinical management fees. Excludes the $265B in gross specialty drug dispensing revenues (primarily drug cost pass-through) — the focus is the pharmacy gross profit layer above drug acquisition cost.
Market Size
| Year | Pharmacy-Dispensed Specialty Revenue | Services/Gross Profit Revenue |
|---|---|---|
| 2024 | ~$265B | ~$22—28B |
| 2025E | ~$286—292B | ~$27—28B |
| 2026E | ~$309—321B | ~$29—30B |
| 2028E | ~$360—388B | ~$32—36B |
Implied services CAGR (2024—2028): ~7—9%
Sub-segment breakdown by channel:
| Channel | Share of Specialty Dispensing (2024) | Services Revenue Margin |
|---|---|---|
| PBM-Affiliated (Accredo, OptumRx, Caremark) | ~65—67% | 4—6% branded; 15—25%+ generics |
| Walgreens Specialty | ~9—10% | 3—5% blended |
| Health System—Owned | ~8—10% | Variable; 340B margin 20—50% on eligible volume |
| Independent/Boutique (PANTHERx, Orsini, Biologics) | ~7—10% | 8—15%+; exclusive network premium |
| Health Plan—Owned (CarelonRx, CenterWell) | ~4—6% | 4—7% |
Top 5 Players by Market Share
| Rank | Company | Est. Dispensing Revenue | Est. Market Share | Est. Services Revenue |
|---|---|---|---|---|
| 1 | CVS Health (CVS Specialty / Caremark) | ~$75—80B | ~28—30% | ~$3—5B |
| 2 | Cigna/Evernorth (Accredo / Express Scripts) | ~$60—70B | ~22—26% | ~$2.5—4B |
| 3 | UnitedHealth/Optum (OptumRx Specialty) | ~$45—55B | ~17—21% | ~$2—3.5B |
| 4 | Walgreens Specialty Pharmacy (Sycamore Partners private LBO since 2025) | ~$24B | ~9—10% | ~$0.8—1.2B |
| 5 | PANTHERx Rare (independent) | ~$3.6B | ~1.5% | ~$0.3—0.5B |
Top 3 combined share: ~65—67%.
Growth Drivers
- Specialty pipeline acceleration. ~75% of ~7,000 pipeline drugs are specialty medicines; IQVIA projects 55%+ of US drug spending by 2028.
- Gene and cell therapy emergence. Ultra-complex therapies (CAR-T, gene replacement) command highest per-prescription service fees; Walgreens built dedicated 18,000 sq. ft. Gene & Cell Services Pharmacy in Pittsburgh.
- Health system channel expansion. Health system—owned specialty pharmacies grew from 15% to 27% of accredited locations (2017—2024).
- Rare/orphan drug growth. Orphan drugs projected at 20% of prescription drug sales by 2026.
- Biosimilar volume expansion. 68 FDA-approved biosimilars through 2024; compresses per-unit margins but expands patient volume.
Risks / Headwinds
- Biosimilar adoption and specialty generic proliferation compressing margins on blockbusters (Humira, Stelara, Enbrel, Keytruda).
- PBM reform and regulatory pressure on spread pricing (FTC found Big 3 earned $7.3B from specialty generic markups 2017—2021).
- DIR fee compression: up 46.8% from 2020 to 2022, totaling $9.5B.
Recent M&A
| Year | Transaction | Value |
|---|---|---|
| 2025 | Cencora acquires OneOncology | $7.4B |
| 2025 | Walgreens taken private by Sycamore Partners | ~$23.7B enterprise |
| 2024 | Cardinal Health acquires Solaris Health | $1.9B |
| 2024 | Cardinal Health acquires Integrated Oncology Network | $1.12B |
| 2024 | BrightSpring IPO (KKR exit) | ~$1B IPO |
2. Prior Authorization & Reimbursement Support
Market Definition
Technology platforms, AI automation tools, and outsourced services for managing end-to-end prior authorization: ePA networks, AI-powered PA automation, utilization management outsourcing, pharma hub/patient access services, and embedded RCM PA modules. The $35B figure frequently cited by Health Affairs represents total admin cost burden — not vendor revenue.
Market Size
| Segment | 2024 US Revenue | 2028E US Revenue | CAGR |
|---|---|---|---|
| Technology Platforms (SaaS/ePA) | ~$1.1B | ~$2.0—2.3B | ~16—20% |
| Service Providers (Outsourced PA / Hub) | ~$4.0B | ~$6.0—6.5B | ~11—13% |
| AI-Powered PA Startups | ~$0.1—0.15B | ~$0.6—1.0B | ~50%+ |
| Total US Market | ~$5.0B | ~$8.5B | ~14% |
Only 31% of medical PA transactions are fully electronic (2023 CAQH Index), indicating substantial conversion opportunity.
Top 5 Players by Market Share
| Rank | Company | Segment | Est. US Revenue | Est. Market Share |
|---|---|---|---|---|
| 1 | EviCore (Evernorth/Cigna) | UM/PA Outsourcing | ~$2.0B | ~35—40% |
| 2 | CoverMyMeds/RxTS (McKesson) | ePA Network + Mfr Services | ~$600—900M | ~12—18% |
| 3 | Surescripts | ePA Infrastructure | ~$200—400M | ~4—8% |
| 4 | Lash Group (CareMetx, post Apr-2026 divestiture from Cencora) | Pharma Hub / Patient Access | ~$400—600M | ~8—12% |
| 5 | AssistRx (WCAS) | Specialty Hub / Therapy Initiation | ~$119M | ~2—3% |
Growth Drivers
- CMS-0057-F mandates FHIR-based PA APIs at all impacted payers by January 2027, forcing procurement across 3,800+ organizations.
- AI automation: manual PA costs ~$14.49/tx vs. ~$5.84 electronic; AI can automate 50—75% of manual tasks.
- Specialty PA volume explosion: Medicare Advantage payers processed ~53M PA requests in 2024 (up from 46M in 2022).
- Surescripts achieved 18-second median PA approval across 76,000+ prescribers by October 2025.
Risks / Headwinds
- Regulatory reform paradox: 10+ states passed PA reform in 2024; gold-carding could reduce PA volume structurally.
- 70% of PA communications remain via fax/phone as of early 2026.
- Change Healthcare ransomware attack (Feb 2024) highlighted systemic fragility.
Recent M&A / Funding
| Date | Transaction | Value |
|---|---|---|
| Jun 2025 | Tennr Series C (IVP / a16z) | $101M ($605M val.) |
| May 2025 | Cohere Health Series C (Temasek) | $90M ($200M total) |
| Oct 2024 | Infinitus Systems Series C (a16z) | $51.5M ($102.9M total) |
| Feb 2024 | WCAS acquires AssistRx | ~$600M valuation |
3. Copay & Financial Assistance Programs
Market Definition
Revenue earned by third-party vendors administering manufacturer-funded financial assistance: copay card/e-voucher administration, PAP management, bridge/quick-start programs, accumulator/maximizer mitigation analytics, and pharma-segment prepaid card delivery. Excludes the ~$21.4B in gross copay spending itself.
Market Size
| Sub-Segment | 2024 US Revenue |
|---|---|
| Copay card / e-voucher administration | $400—500M |
| PAP management & free goods services | $150—200M |
| Bridge / quick-start program admin | $75—100M |
| Accumulator/maximizer mitigation | $50—100M |
| Prepaid debit card delivery (pharma) | $30—50M |
| Total US Market | ~$950M—$1.1B (mid: ~$1.0B) |
| Scenario | 2024 | CAGR | 2028E |
|---|---|---|---|
| Base Case | ~$1.0B | 8—10% | ~$1.4B |
| Bull Case | ~$1.0B | 11—13% | ~$1.6B |
| Bear Case | ~$1.0B | 5—6% | ~$1.2B |
Top 5 Players by Market Share
| Rank | Company | Est. 2024 Revenue | Est. Market Share | Ownership |
|---|---|---|---|---|
| 1 | ConnectiveRx | ~$116M copay segment (27% of total; 2024-2025 copay est. ~$130-150M) | ~13—15% | PE-backed (Genstar Capital per public sources) |
| 2 | CareMetx + Lash/TheraCom (post Apr-2026 Cencora divestiture) | ~$160—250M directional combined hub / affordability estimate | ~18—26% | General Atlantic-led CareMetx platform |
| 3 | Valeris (Mercalis / legacy TrialCard) | ~$80—120M affordability segment equivalent | ~9—12% | PE-backed (Permira majority) |
| 4 | AssistRx | scale not publicly disclosed | directional top-five platform | WCAS-backed |
| 5 | Paysign (PAYS) | $33.89M pharma revenue (FY2025) | ~2—4% | Public (NASDAQ: PAYS) |
ConnectiveRx leads with 150+ pharma clients. Paysign reported FY2025 pharma revenue of $33.89M, up 167.8% year over year, and exited 2025 with 131 active patient-affordability programs.
Growth Drivers
- Specialty pipeline: 400—500+ specialty agents in late-stage, each launching with 3—10 year copay programs.
- Gross-to-net bubble: reached $356B in 2024, intensifying manufacturer pressure for copay program sophistication.
- Accumulator/maximizer mitigation: $6.9B of $21.4B diverted (37% of total copay value) in 2024; 84% of commercially insured lives in accumulator-available plans.
- IRA Part D changes: $2,000 OOP cap drives program restructuring mandates.
Risks / Headwinds
- IRA drug price negotiation may reduce specialty pricing, lessening copay program necessity.
- Regulatory uncertainty on accumulators (25 states + DC enacted bans covering ~17% of commercial lives; ERISA plans unprotected).
- PBM disintermediation: CVS PrudentRx and Express Scripts SaveOnSP position Big 3 as competitors.
Recent M&A
| Date | Transaction | Significance |
|---|---|---|
| Aug 2025 | EVERSANA + Waltz Health merger | Pharma commercialization + drug access platform |
| May 2025 | PharmaCord + Mercalis → Valeris (Permira) | ~3,000+ employee independent patient access platform |
| Feb 2024 | WCAS acquires AssistRx | ~$600M valuation |
4. Market Access Consulting
Market Definition
US consulting services sold to pharma manufacturers: payer strategy and formulary access, pricing and reimbursement strategy, HEOR, market access launch planning, payer engagement, and government affairs/policy consulting. Excludes hub/patient services, CRO-executed HEOR, standalone regulatory, and enterprise strategy consulting not primarily market-access focused.
Market Size
| Sub-Segment | 2024 US Revenue |
|---|---|
| Pricing & reimbursement strategy | ~$900M |
| HEOR consulting | ~$820M |
| Payer strategy & formulary access | ~$750M |
| Launch market access planning | ~$600M |
| Government affairs & policy consulting | ~$350M |
| Total | ~$3.4B |
| Year | US Market | Notes |
|---|---|---|
| 2024 | $3.4B | Central estimate |
| 2026E | $4.1B | IRA price negotiation compliance peak |
| 2028E | $5.0B | ~10% CAGR |
Highly fragmented: top 5 hold ~15—20% combined share; 200+ boutiques fill the remainder.
Top 5 Players by Market Share
| Rank | Company | Est. US MA Consulting Revenue | Est. Market Share |
|---|---|---|---|
| 1 | Precision AQ | ~$185—210M | ~5.5—6.5% |
| 2 | Xcenda (Cencora) | ~$120—140M | ~3.5—4.5% |
| 3 | Trinity Life Sciences (Kohlberg PE) | ~$80—120M | ~2.5—3.5% |
| 4 | ZS Associates (Value & Access) | ~$100—165M | ~2.5—3.5% |
| 5 | Avalere Health (Bridgepoint PE) | ~$80—100M | ~2.5—3.0% |
Growth Drivers
- IRA Medicare Drug Price Negotiation: reductions of 38—79% on first 10 drugs; 20+ drugs/year entering negotiation by 2028.
- Specialty launch complexity: average first-year launch revenues fell from $140M (2018) to $60M (2022).
- RWE as regulatory/payer currency: FDA 2024 RWE guidance and CMS use in IRA negotiations.
- PBM reform: 2026 Consolidated Appropriations Act requires 100% rebate pass-through in Medicare Part D.
Risks / Headwinds
- IRA policy uncertainty and pipeline rationalization reducing total consulting engagements.
- Insourcing by large pharma (internal HEOR teams) and AI displacement of commodity deliverables.
Recent M&A
| Date | Target | Acquirer |
|---|---|---|
| Nov 2025 | EVERSANA APACME Advisory | Trinity Life Sciences |
| Aug 2024 | PHAR (HTA/HEOR) | ADVI Health (Sheridan Capital) |
| Jun 2024 | Mtech Access + Delta Hat | Petauri Health (Oak Hill) |
| 2022 | Multiple firms → Lumanity | Arsenal Capital Partners ($106.9M rev by 2022) |
5. Data Analytics & Real-World Evidence
Market Definition
Pharma-specific data platforms and subscriptions (licensed claims, patient-level, prescriber, formulary data), RWE generation services, commercial analytics platforms (SaaS for sales force effectiveness, launch tracking, market share), GTN/channel analytics, and AI-powered analytics layers sold to life sciences companies. Excludes general healthcare IT, payer actuarial analytics, and non-pharma hospital analytics.
Market Size
| Segment | 2024 US Revenue |
|---|---|
| IQVIA TAS (US-attributable) | ~$2.8—3.0B |
| Veeva Commercial Data (Compass Suite) | ~$0.45—0.55B |
| Symphony Health (ICON) | ~$0.20B |
| Komodo Health | ~$0.25—0.35B |
| ConcertAI | ~$0.15—0.20B |
| IntegriChain | ~$0.12—0.15B |
| Other (Flatiron Health, HealthVerity, Datavant + Aetion (combined RWE platform post Jul-2025 Datavant acquisition), OM1, TriNetX, Claritas) | ~$0.5—1.0B |
| Total | ~$8.0—9.5B (mid: $8.5B) |
| Year | US Market |
|---|---|
| 2024 | ~$8.5B |
| 2026E | ~$10.8B |
| 2028E | ~$13.8B (13% CAGR) |
RWE specifically: ~$1.8—2.2B US in 2024, growing to ~$3.5B by 2028 at 14.8% CAGR.
Top 5 Players by Market Share
| Rank | Company | Est. US Revenue (2024) | Est. US Share |
|---|---|---|---|
| 1 | IQVIA (TAS segment) | ~$2.8—3.0B | ~33—35% |
| 2 | Veeva Systems (Commercial) | ~$0.45—0.55B | ~5—7% |
| 3 | Komodo Health | ~$0.25—0.35B | ~3—4% |
| 4 | ConcertAI | ~$0.15—0.20B | ~2—3% |
| 5 | IntegriChain | ~$0.12—0.15B | ~1.5—2% |
IQVIA dominates with ~33—35% share. Veeva Compass Suite (launched Jan 2024) is the primary competitive threat.
Growth Drivers
- FDA RWE framework: 2024 guidance enables EHR and claims data for approvals and label expansions.
- Value-based contracting: 58%+ of US payers had at least one OBC as of 2022; cell/gene pricing accelerates adoption.
- AI/ML integration: Komodo Marmot, ConcertAI CARAai, IQVIA Connected Intelligence reduce time-to-insight from weeks to minutes.
- Specialty/rare disease complexity: patient-finding, channel analytics, SP data, and post-market RWE mandates under accelerated approval.
Risks / Headwinds
- Data privacy regulation (CPRA, state health data protection acts) creating compliance complexity.
- Veeva/IQVIA price competition compressing data licensing pricing industry-wide.
- Pharma budget sensitivity to IRA revenue pressure (IQVIA TAS growth slowed to ~1% in Q1 2024 before recovering).
Recent M&A
| Date | Transaction |
|---|---|
| Jan 2024 | Veeva Compass Suite full commercial launch |
| Nov 2023 | Nordic Capital majority stake in IntegriChain |
| Jun 2024 | IntegriChain acquires BridgeView Data |
| May 2025 | Komodo Health—Nasdaq Medical Claims Insights partnership |
6. Pharma Commercial Technology
Market Definition
Pure SaaS and software + services platforms for pharma/biotech commercial functions: CRM and field force automation, omnichannel engagement, commercial analytics and AI/NBA, HCP master data and commercial data products, and revenue management/compliance software. Excludes Veeva Vault R&D/regulatory, CRO services, pharmacovigilance, and patient services/hub platforms.
Market Size
| Sub-Segment | 2024E US | 2028E US | CAGR |
|---|---|---|---|
| CRM / Field Force | ~$820M | ~$1,120—1,200M | 8—10% |
| Omnichannel Engagement | ~$550M | ~$800—870M | 10—12% |
| Revenue Management | ~$165M | ~$210—225M | 6—8% |
| AI / Commercial Analytics | ~$250M | ~$435—520M | 15—20% |
| Commercial Data Products | ~$550M | ~$750—810M | 8—10% |
| Total | ~$2.35B | ~$3.3—3.6B | ~9—11% |
Top 5 Players by Market Share
| Rank | Player | Est. US Revenue (2024) | Est. US Share |
|---|---|---|---|
| 1 | Veeva Systems (Pure SaaS + data) | $700—800M | ~30—35% |
| 2 | IQVIA (TAS commercial portion) | $250—350M | ~10—15% |
| 3 | Model N (Vista Equity) | $150—180M | ~6—8% |
| 4 | Salesforce (Life Sciences Cloud) | $50—100M | ~2—4% |
| 5 | Aktana / PharmaForceIQ | $40—70M | ~2—3% |
Veeva holds ~80% global CRM market share with 1,500+ customers. Top 3 control ~50—55% of total market.
Growth Drivers
- Vault CRM migration upsell (2025—2029): mandatory migration creates ACV expansion; 125+ customers live by March 2026.
- AI/NBA becoming mandatory: 30—40% HCP engagement improvement and 4—10% sales lift.
- Specialty launch complexity: 63+ NMEs approved in 2024; cell/gene requires personalized HCP engagement.
- IRA reporting and 340B complexity driving Model N adoption.
Risks / Headwinds
- IRA pricing pressure compressing drug revenues and commercial budgets; $200B patent cliff 2024—2028.
- Salesforce LSC + IQVIA partnership creating credible second platform; OCE sunset by 2029.
- Vault CRM execution risk with concentrated migration timeline.
Recent M&A / Strategic Shifts
| Date | Event |
|---|---|
| Jan 2026 | Aktana acquired by PharmaForceIQ (first “optichannel-in-a-box” specialist) |
| Oct 2025 | Salesforce LSC general availability (70+ customers incl. Pfizer, Takeda) |
| Apr 2024 | IQVIA—Salesforce expanded partnership; OCE licensed to Salesforce |
| Apr 2024 | Model N taken private by Vista Equity ($1.25B; ~4.8x forward revenue) |
Cross-Category Themes
1. The IRA as Dominant Structural Catalyst
The IRA reshapes all six categories simultaneously. Market access consulting sees the most direct demand surge; commercial technology faces the sharpest headwind from compressed drug revenues; specialty pharmacy faces dispensing margin compression. The IRA is simultaneously the sector’s largest growth driver and primary cost pressure.
2. Vertical Integration and Platform Consolidation
PBMs integrating into specialty pharmacy (CVS/Caremark, Evernorth/Accredo), PA outsourcing (EviCore), and copay administration (PrudentRx, SaveOnSP). PE sponsors (Arsenal/Lumanity, Kohlberg/Trinity, Permira/Valeris) building scale platforms. CRM consolidating to two platforms (Veeva Vault CRM vs. Salesforce LSC/IQVIA).
3. AI as Both Opportunity and Disruptor
Asymmetric effects: PA voice AI at 50%+ CAGR (new revenue); commercial AI/NBA at 15—20% CAGR (mandatory infrastructure); RWE AI reduces time-to-insight (platform stickiness); consulting AI automates commodity work (margin compression). Winners have proprietary data moats.
4. Specialty Drug Complexity as Universal Tailwind
~75% of ~7,000 pipeline drugs are specialty; projected 55%+ of US spending by 2028. Each launch requires all six service categories. The specialty pipeline is the universal demand engine.
5. Regulatory Complexity as Sustainable Demand Generator
CMS-0057-F FHIR mandate (3,800+ payer procurement wave), PBM reform (2026 CAA), FDA RWE guidance, increasing UM — regulatory complexity accumulates, creating durable recurring demand.
6. Private Equity as Market Architect
PE capital reshaping market access consulting, copay administration, and commercial technology. Entry multiples of 10—15x EBITDA reflect conviction in recurring revenue — especially platforms with embedded compliance or proprietary data assets.
Consolidated June 2026 from the April 2026 six-category sizing model and the 2025 Houlihan Lokey / Bourne Partners market-update stack. All estimates represent analytical synthesis of public filings, industry research, and sector-specific data; they are not audited figures.
Related Wiki Vendors (Auto)
Auto-generated cross-references closing audit-surfaced link gaps. Vendors named in the prose above without inline links are listed here so the wiki graph is queryable.
- AssistRx
- Avalere Health
- Cardinal Health
- CareMetx
- Cohere Health
- ConcertAI
- ConnectiveRx
- CoverMyMeds
- CVS Health
- EVERSANA
- Infinitus Systems
- IntegriChain
- IQVIA
- Komodo Health
- Lumanity
- Model N
- PANTHERx Rare
- Petauri
- Precision AQ
- Surescripts
- Tennr
- Trinity Life Sciences
- Veeva Systems
- Walgreens Specialty Pharmacy
- Xcenda (Cencora)
- ZS Associates
Rx Almanac maintains a private source register for each article. Material public claims are cited inline; sourcing standards and correction policy are described in our methodology.
Related Articles
Analysis
340B TPA Comparison: Apexus vs Sentry Data Systems vs Macro Helix
Covered-entity 340B TPA comparison for Apexus, Sentry Data Systems, and Macro Helix, with manufacturer channel-risk implications.
Analysis
Cell and Gene Therapy Services Comparison: Orsini vs PANTHERx vs Onco360 vs Accredo vs CVS
This comparison supports a manufacturer-side CGT launch decision: which specialty-pharmacy and access partner can handle product-specific requirements around cryogenic handling, REMS, treatment-center coordination, payer access, hub orchestration, and long-term follow-up.
Analysis
Oncology Pharmacy Network Design: LDD Segmentation and Specialty Pharmacy Selection
This analysis gives manufacturer launch teams a practical oncology specialty pharmacy network design framework: when to use Onco360, when to include PBM-owned SPs, when health-system pharmacies matter, and when independent specialists or rare-disease pharmacies should be in the network.
Get more analysis like this
Weekly pharma vendor intel: new comparisons, market updates, and expert insights.
Found an inaccuracy? Tell us.
Suggest a correction